Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an associate professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2 and Senior. His clinical and preclinical research interests include the detection and characterization of high risk, advanced and metastatic prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404).  He is also involved in the development of new radioligand therapeutics.

His research program has four aims: 1) To develop a dynamic imaging method based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow predicting the patient’s response to antiandrogen treatments. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to identify the very high risk prostate cancer and to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells.  4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.

L'Hôtel-Dieu de Québec
6, rue McMahon
0624
Québec, Québec
Canada G1R 2J6
80 entries « 1 of 8 »

Goulet CR, Pouliot F

TGFβ Signaling in the Tumor Microenvironment.

Journal Article

Adv Exp Med Biol, 1270 , pp. 89-105, 2021, ISSN: 0065-2598.

Abstract | Links:

Shiff B, Breau RH, Patel P, Mallick R, Tanguay S, So A, Lavallee L, Moore R, Rendon R, Kapoor A, Pouliot F, Finelli A, Bhindi B, Lattouf JB, Basappa N, Wood L, Heng D, Bjarnason G, Drachenberg D

Reply By Authors.

Journal Article

J Urol, pp. 101097JU000000000000123003, 2020, ISSN: 0022-5347.

| Links:

Asselin C, Finelli A, Breau RH, Mallick R, Kapoor A, Rendon RA, Tanguay S, Pouliot F, Fairey A, Lavallee LT, Bladou F, Kawakami J, So AI, Richard PO

Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence?

Journal Article

Urol Oncol, 38 (10), pp. 798.e9-798.e16, 2020, ISSN: 1078-1439.

Abstract | Links:

Dragomir A, Nazha S, Wood LA, Rendon RA, Finelli A, Hansen A, So AI, Kollmannsberger C, Basappa NS, Pouliot F, Soulieres D, Heng DYC, Kapoor A, Tanguay S

Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.

Journal Article

Urol Oncol, 38 (10), pp. 799.e1-799.e10, 2020, ISSN: 1078-1439.

Abstract | Links:

Sun R, Breau RH, Mallick R, Tanguay S, Pouliot F, Kapoor A, Lavallee LT, Finelli A, So AI, Rendon RA, Fairey AS, Lattouf JB, Kawakami J, Bhindi B, Basappa NS, Wood LA, Bjarnason GA, Heng DYC, Bansal R

Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system.

Journal Article

Can Urol Assoc J, 2020, ISSN: 1911-6470.

Abstract | Links:

Saad F, Fleshner N, Pickles T, Niazi T, Lukka H, Pouliot F, Martins I, Klotz L

Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.

Journal Article

J Urol, 204 (3), pp. 416-426, 2020, ISSN: 0022-5347.

Abstract | Links:

Hotte SJ, Finelli A, Chi KN, Canil C, Fleshner N, Kapoor A, Kolinsky M, Malone S, Morash C, Niazi T, Noonan KL, Ong M, Pouliot F, Shayegan B, So AI, Sorabji D, Hew H, Park-Wyllie L, Saad F

Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists.

Journal Article

Can Urol Assoc J, 2020, ISSN: 1911-6470.

Abstract | Links:

Ghavimi S, Saarela O, Pouliot F, Rendon RA, Finelli A, Kapoor A, Moore RB, Breau RH, Lavallee L, Lacombe L, Fairey A, Jewett M, Liu Z, Tanguay S, Black PC

Achieving the "trifecta" with open versus minimally invasive partial nephrectomy.

Journal Article

World J Urol, 2020, ISSN: 0724-4983.

Abstract | Links:

Shiff B, Breau RH, Patel P, Mallick R, Tanguay S, So A, Lavallee L, Moore R, Rendon R, Kapoor A, Pouliot F, Finelli A, Bhindi B, Lattouf JB, Basappa N, Wood L, Heng D, Bjarnason G, Drachenberg D

Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma.

Journal Article

J Urol, pp. 101097JU0000000000001230, 2020, ISSN: 0022-5347.

Abstract | Links:

Kokorovic A, So AI, Hotte SJ, Black PC, Danielson B, Emmenegger U, Finelli A, Niazi T, Pouliot F, Shayegan B, Sridhar S, Vigneault E, Loblaw A, Rendon R

A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association.

Journal Article

Can Urol Assoc J, 14 (6), pp. 163-168, 2020, ISSN: 1911-6470.

| Links:

80 entries « 1 of 8 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
  • National Program on Radioligand Therapy for Prostate Cancer, Subvention, Cancer de la prostate Canada, from 2018-01-01 to 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapie ciblée, Subvention, Fonds de recherche du Québec - Santé, ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer, from 2018-04-01 to 2021-03-31
  • Projet de recherche sur le cancer de la prostate intitulé Ironman , Subvention, Fondation du CHU de Québec, from 2020-03-24 to 2021-03-23
  • Surveillance of Complex Renal Cysts: The SOCRATIC study, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2028-09-30
  • Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques, Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2019-07-01 to 2023-06-30

Recently finished projects

  • Characterizing high-risk prostate tumor heterogeneity at single cell level to identify castration-resistant prostate cancer progression molecular profile , Subvention, Association canadienne d'urologie, from 2019-07-29 to 2020-03-31
  • Développement et utilisation de systèmes d’amplification transcriptionnelle multigéniques à des fins diagnostiques et thérapeutiques pour améliorer la prise en charge du cancer de la prostate., Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2017-07-01 to 2019-06-30
  • Modeling Prostate Cancer in 30 using tissue engineering , Subvention, Association canadienne d'urologie, from 2019-09-11 to 2020-09-10
  • Support statistique pour la recherche en Urologie-oncologie, Subvention, Fondation du CHU de Québec, from 2019-03-25 to 2020-03-24
Data provided by the Université Laval research projects registery